Advertisement

Cancer Causes & Control

, Volume 30, Issue 1, pp 97–101 | Cite as

The rate of the recurrent MSH6 mutations in Ashkenazi Jewish breast cancer patients

  • Rinat Bernstein-Molho
  • Yael Laitman
  • Hagit Schayek
  • Sarah Iomdin
  • Eitan FriedmanEmail author
Original paper

Abstract

Background

Whether breast cancer (BC) should be considered within the spectrum of tumors in Lynch syndrome (LS) is unsettled. Recently, MSH6 and PMS2 germline mutations have reportedly been associated with an increased BC risk and with hereditary breast and ovarian cancer (HBOC) phenotype. We assessed the rates of the recurring Ashkenazi Jewish (AJ) mutations in the MSH6 gene (c.3984_3987dupGTCA and c.3959_3962delCAAG) in AJ cases with seemingly sporadic BC or HBOC phenotype, who were negative for the founder AJ BRCA1/2 mutations.

Methods

All AJ individuals, affected with BC ≤ 70 years and/or ovarian cancer at any age who were counseled, genotyped and tested negative for the BRCA1/2 founder mutations between January 2010 and February 2018 at the Oncogenetics unit, Sheba Medical Center, were genotyped for the AJ mutations in MSH6.

Results

Of 1016 genotyped participants (815 BC cases, 132 ovarian cancer cases, and 69 with more than one cancer), five carriers (0.49%) of the recurring AJ mutations in MSH6 were identified. All had BC, and two had personal history of additional cancers (pancreatic, endometrial, colorectal). The rate of MSH6 mutations was 0.93% (4/429) when considering only cases with a personal or first-degree relative with LS-related cancer, and 0.17% (1/587) of cases with second-degree relative or no family history of LS-related cancers (p = 0.087).

Conclusions

Our data suggest the spectrum of genotyped mutations in AJ BC patients with a personal or family history of LS-related cancers should be expanded. These data should be validated in other populations with a similar phenotype.

Keywords

Breast cancer MSH6 Lynch syndrome Ashkenazi Jews 

Notes

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Win AK, Lindor NM, Jenkins MA (2013) Risk of breast cancer in Lynch syndrome: a systematic review. Breast Cancer Res BCR 15:R27CrossRefGoogle Scholar
  2. 2.
    Roberts ME, Jackson SA, Susswein LR, Zeinomar N, Ma X, Marshall ML et al (2018) MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer. Genet Med.  https://doi.org/10.1038/gim.2017.254 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Therkildsen C, Ladelund S, Smith-Hansen L, Lindberg LJ, Nilbert M (2017) Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types. Br J Cancer 117(11):1702–1710CrossRefGoogle Scholar
  4. 4.
    Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W et al (2012) Risks of less common cancers in proven mutation carriers with Lynch syndrome. J Clin Oncol 30:4409–4415CrossRefGoogle Scholar
  5. 5.
    Espenschied CR, LaDuca H, Li S, McFarland R, Gau C-L, Hampel H (2017) Multigene panel testing provides a new perspective on Lynch syndrome. J Clin Oncol 35:2568–2575CrossRefGoogle Scholar
  6. 6.
    Robson M, Dabney MK, Rosenthal G, Ludwig S, Seltzer MH, Gilewski T et al (1997) Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test 1:47–51CrossRefGoogle Scholar
  7. 7.
    Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14:185–187CrossRefGoogle Scholar
  8. 8.
    Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI et al (1998) Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 63:45–51CrossRefGoogle Scholar
  9. 9.
    Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C et al (1999) Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91:1241–1247CrossRefGoogle Scholar
  10. 10.
    Tobias DH, Eng C, McCurdy LD, Kalir T, Mandelli J, Dottino PR et al (2000) Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients. Gynecol Oncol 78:148–151CrossRefGoogle Scholar
  11. 11.
    Raskin L, Schwenter F, Freytsis M, Tischkowitz M, Wong N, Chong G et al (2011) Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome. Clin Genet 79:512–522CrossRefGoogle Scholar
  12. 12.
    Mukherjee B, Rennert G, Ahn J, Dishon S, Lejbkowicz F, Rennert HS et al (2011) High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation. Gastroenterology 140:1919–1926CrossRefGoogle Scholar
  13. 13.
    Foulkes WD, Thiffault I, Gruber SB, Horwitz M, Hamel N, Lee C et al (2002) The founder mutation MSH2*1906G→C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet 71:1395–1412CrossRefGoogle Scholar
  14. 14.
    Laitman Y, Herskovitz L, Golan T, Kaufman B, Paluch SS, Friedman E (2012) The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer. Fam Cancer 11:243–247CrossRefGoogle Scholar
  15. 15.
    Barak F, Milgrom R, Laitman Y, Gemer O, Rabinovich A, Piura B et al (2010) The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients. Gynecol Oncol 119:511–515CrossRefGoogle Scholar
  16. 16.
    Schayek H, De Marco L, Starinsky-Elbaz S, Rossette M, Laitman Y, Bastos-Rodrigues L et al (2016) The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil. Cancer Genet 209:50–52CrossRefGoogle Scholar
  17. 17.
    Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP (2015) Milestones of Lynch syndrome: 1895–2015. Nat Rev Cancer 15:181–194CrossRefGoogle Scholar
  18. 18.
    Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K et al (2015) Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 121:25–33CrossRefGoogle Scholar
  19. 19.
    Wong ESY, Shekar S, Met-Domestici M, Chan C, Sze M, Yap YS et al (2016) Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore. NPJ Genom Med 1:15003CrossRefGoogle Scholar
  20. 20.
    Walsh T, Mandell JB, Norquist BM, Casadei S, Gulsuner S, Lee MK et al (2017) Genetic predisposition to breast cancer due to mutations other than BRCA1 and BRCA2 founder alleles among Ashkenazi Jewish women. JAMA Oncol 3:1647–1653CrossRefGoogle Scholar
  21. 21.
    Goldberg Y, Porat RM, Kedar I, Shochat C, Galinsky D, Hamburger T et al (2010) An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC. Fam Cancer 9:141–150CrossRefGoogle Scholar
  22. 22.
    Shah TA, Guraya SS (2017) Breast cancer screening programs: review of merits, demerits, and recent recommendations practiced across the world. J Microsc Ultrastruct 5:59–69CrossRefGoogle Scholar
  23. 23.
    Davies H, Morganella S, Purdie CA, Jang SJ, Borgen E, Russnes H et al (2017) Whole-genome sequencing reveals breast cancers with mismatch repair deficiency. Cancer Res 77:4755CrossRefGoogle Scholar
  24. 24.
    Research C for DE and Approved Drugs—FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm. Accessed 22 May 2018

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Rinat Bernstein-Molho
    • 1
    • 3
  • Yael Laitman
    • 2
  • Hagit Schayek
    • 2
  • Sarah Iomdin
    • 2
  • Eitan Friedman
    • 2
    • 3
    • 4
    Email author
  1. 1.Breast Cancer Center, Oncology InstituteChaim Sheba Medical CenterTel-HashomerIsrael
  2. 2.Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human GeneticsChaim Sheba Medical CenterTel-HashomerIsrael
  3. 3.Sackler School of MedicineTel-Aviv UniversityTel-AvivIsrael
  4. 4.Oncogenetics Unit, Institute of Human GeneticsSheba Medical CenterTel-HashomerIsrael

Personalised recommendations